SCHEMBL21236089

SCHEMBL21236089

CCNS(=O)(=O)CCCN

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RELA Q04206 4/20 0.49
APP P05067 1/20 0.42
ALDH1A1 P00352 2/20 0.41
TSHR P16473 2/20 0.41
GMNN O75496 1/20 0.41
LMNA P02545 1/20 0.41
TP53 P04637 1/20 0.41
MAPK1 P28482 1/20 0.41
THPO P40225 1/20 0.41
HBB P68871 1/20 0.41
PMP22 Q01453 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
CA12 O43570 1/20 0.31
CA7 P43166 1/20 0.31
CA14 Q9ULX7 1/20 0.31
DNM1 Q05193 4/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6263448 0.85
SCHEMBL2010127 0.80 CA1 (0.44) RELAALDH1A1LMNATP53MAPK1
SCHEMBL7432483 0.78 RELA (0.50) RELACA1CA2CA12CA7
SCHEMBL3343164 0.76 RELA (0.33) RELACA1CA2CA12CA7
SCHEMBL11883426 0.76 RELA (0.53) RELACA1CA2
SCHEMBL19776014 0.76 RELA (0.53) RELACA1CA2
SCHEMBL6830674 0.76 RELA (0.33) RELAALDH1A1TSHRCA1CA2
Hydrochloric Acid SCHEMBL28232067 0.76 RELA (0.49) RELACA1CA2CA12CA7
SCHEMBL7691856 0.76 RELA (0.53) RELACA1CA2
SCHEMBL11933655 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11591301-B2 Indoleamine-2,3-dioxygenase inhibitor, preparation method therefor and use thereof HINOVA PHARMACEUTICALS INC. (CN) 2023-02-28 US disclosed
US-20210047281-A1 INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF HINOVA PHARMACEUTICALS INC. (CN) 2021-02-18 US disclosed
WO-2019149255-A1 INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF 成都海创药业有限公司 2019-08-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11591301-B2 Indoleamine-2,3-dioxygenase inhibitor, preparation method therefor and use thereof IDO1, IDO2, TPH1 RELA 2501/4885APP 689/4885ALDH1A1 741/4885
US-20210047281-A1 INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF IDO1, IDO2, TPH1 RELA 2501/4885APP 689/4885ALDH1A1 741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.